Suggested remit: To appraise the clinical and cost effectiveness of foslevodopa-foscarbidopa subcutaneous infusion within its marketing authorisation for treating Parkinson’s disease with motor fluctuations [ID3876]
 
Status Awaiting development
Process STA 2018
ID number 3876

Provisional Schedule

Expected publication 01 March 2023

Project Team

Project lead Michelle Adhemar

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
21 October 2021 Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin during early April 2022 when we will write to consultees and commentators about how they can get involved.
23 July 2021 Please note that following on from information received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early January 2022 when we will write to you about how you can get involved.
07 May 2021 Please note that the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in late October 2021.
21 April 2021 (10:00) Scoping workshop
01 March 2021 - 29 March 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance